

RECEIVED
CENTRAL FAX CENTER

OCT 26 2006

FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

October 26, 2006

TO: Examiner Rawlings
Group 1643
(571) 272-0836

FROM Justin D. Karjala
Celera Genomics Corp.
(240) 453-3812

FAX NO: (571) 273-8300

OF PAGES (incl. cover): 7

Re: U.S. Serial No. 10/800,865, filed March 16, 2004
Entitled "ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC ACID
MOLECULES ENCODING THESE HUMAN RAS-LIKE PROTEINS, AND
USES THEREOF"
Attorney Docket No.: CL001143-DIV

A Preliminary Amendment (Restriction Election) in the above-identified application follows. No fee is due for this submission.

The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail.

Thank you for your cooperation.

RECEIVED
CENTRAL FAX CENTER

OCT 26 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jane YE et al.

Art Unit: 1643

Serial No.: 10/800,865

Examiner: S. Rawlings

Filed: March 16, 2004

Atty. Docket: CL001143-DIV

For: ISOLATED HUMAN RAS-LIKE
PROTEINS, NUCLEIC ACID MOLECULES
ENCODING THESE HUMAN RAS-LIKE
PROTEINS, AND USES THEREOF

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

By Facsimile

Sir:

This is in response to an Office Action mailed on September 27, 2006 from Examiner Rawlings in which a restriction requirement was issued for the above-referenced application.

In response to the restriction requirement, Applicants hereby elect, with traverse, claim group II (claim 3, drawn to antibodies) for examination and have canceled claims corresponding to the non-elected groups III-XIII.

However, applicants respectfully request that the Examiner reconsider the claim division of the restriction requirement and combine group II (drawn to antibodies) with group I (drawn to polypeptides).

In particular, examination of the antibody claims of group II, in which the antibodies claimed in the group II claims selectively bind the polypeptides that are claimed in the group I claims (as in the instant situation), is based in part on search and examination of the amino acid sequence of the polypeptides claimed in the group I claims. Therefore, because the search and examination necessary to examine the claims of group II inherently includes a search of the amino acid sequence of the polypeptides

Serial No. 10/800,865

claimed in the group I claims, a search and examination of the group II claims inherently includes a search and examination of the group I claims. Thus, it is believed that the effort required to search and examine both groups I and II together is not substantially greater than the effort required to search and examine group II alone, and therefore search and examination of the claims of groups I and II combined would not unduly burden the Examiner with additional review issues.

Accordingly, Applicants are hereby amending claim 3 and presenting new claims 24-36 drawn to antibodies and respectfully request entry, search, and examination of these antibody claims. Additionally, should the Examiner reconsider the restriction requirement based on the above remarks and combine group I (polypeptides) with group II (antibodies), Applicants are also hereby amending claims 1-2 and presenting new claims 37-38 drawn to polypeptides and respectfully request entry, search, and examination of these polypeptide claims together with the antibody claims.

Please amend the application as follows: